Sinopharm Group Co. Ltd (“Sinopharm”) successfully completed its H-share follow-on offering on December 1st, 2014 (“The Offering”). A total 198.8 million new H-shares were offered in this deal, raising HKD 5.65 billion (equivalent to ~ USD 728 million)and the Offering was priced at HK$28.40. CICC acted as Joint Lead Placing Agent and Sole Settlement Agent. Such financing strategy has achieved fruitful results and has added strong momentum for Sinopharm to materialize and maintain its dominance in the pharmaceutical sector.